Filters
Hikma launches Rufinamide Oral Suspension, 40 mg/mL
Press Release, Product
Hikma assigned investment grade status from Fitch Ratings
Press Release, Corporate
Hikma and Arecor expand collaboration with new agreement to develop and commercialise ready-to-administer medicine
Press Release, Product
Hikma provides update on status of ANDA for generic Advair Diskus®
Press Release, Corporate
Hikma launches Azacitidine for Injection
Press Release, Product
Hikma Ventures Participates in CAD4.0 million Series A Financing Round for SeamlessMD to Expand Digital Patient Engageme...
Press Release, Corporate
Hikma improves its performance in FTSE4Good Index
Press Release, Corporate
Hikma delivers strong first half performance and raises full year guidance
Press Release, Corporate
Hikma improves performance in FTSE4Good Index
Press Release, Corporate
Hikma launches Dacarbazine for Injection, USP
Press Release, Product
Hikma successfully completes $500 million 5-year Eurobond issue
Press Release, Corporate
Transaction in Own Shares and Total Voting Rights and Capital
Press Release, Corporate
Hikma announces buy back of up to approximately £295 million of shares from Boehringer Ingelheim
Press Release, Corporate
Hikma and Sun Pharma enter into exclusive licensing agreement for ILUMYA™ for the Middle East and North Africa region
Press Release, Corporate